Oncology

According to research published in the journal Clinical Cancer Research, immunotherapy right after chemotherapy can piggy back on the immune modifications caused by the chemotherapy, to improve response to treatment in ovarian cancer.

CMS has developed the Oncology Care Model (OCM) to provide physician practices that furnish chemotherapy treatment the option of payment arrangements that include financial and performance accountability for episodes of care for cancer patients. This article presents an overview of the model and guidelines that can help meet the quality and performance measures for OCM participation.

A collaborative effort by urologists and public health specialists from various healthcare systems around the country has found that PSA levels measured in midlife (45 to 59 years of age) are a strong predictor of future lethal prostate cancer.

A new study, published in the Journal of Thoracic Oncology, has found that chemotherapy administered in patients with stage I disease, following a complete resection, can have a significant impact on their median 5-year overall survival.

What we're reading, June 14, 2016: CMS has proposed requiring Medicare hospitals follow new antibiotic controls; New York poised to expand access to breast cancer screening; and clinical trials are seeing more success.

The new Medicare Part B proposal from CMS has been controversial, and Steve Miller, MD, senior vice president and chief medical officer of Express Scripts, understands both sides of the argument. While he appreciates CMS' dedication to innovation, the demonstration may drive up payer costs.

What we're reading, June 13, 2016: the World Health Organization is recommending women in Zika-infected areas delay pregnancy; one FDA regulator feels too many drug makers are chasing the same treatments in cancer care; and risky behaviors among American teenagers are down.

A survey conducted among members of the South Carolina Academy of Family Physicians found that although most family physicians reported that they discussed low-dose computed tomography screening (LDCT) with their patients, referrals were low

This week in managed care, the top stories included discussions on biomarkers and financial toxicity at the annual meeting of the American Society of Clinical Oncology, and a preview of the 76th Scientific Sessions of the American Diabetes Association.

Results presented at the European League Against Rheumatism Annual Congress have confirmed that Systemic Lupus Erythematosus can increase the risk of developing cervical cancer in women.

The Colombian government is forcing pharmaceutical giant Novartis to lower prices of its leukemia medicine, imatinib (Gleevec).

Only half of US veterans who died from cancer received palliative care, while the use of hospice depended upon the care environment. Overall, there was a gap between the percentage of patients who received palliative care and recommended use.

A group in Israel presented a study that evaluated the price trend of 30 anticancer agents following their launch, and found that prices may increase by as much as 44% even after adjusting for inflation.

As cancer care stakeholders move through processes of creating, deploying, and reporting quality metrics, it is important to remember that these measures alone are not sufficient to bring better care to patients.

The German-Australian AML Study Group, one of the largest global groups evaluating treatments for acute myeloid leukemia (AML), has published results in the New England Journal of Medicine that now classifies AML into 11 classes based on the harbored genetic mutations.

A poster presented at the annual meeting of the American Society of Clinical Oncology (ASCO) found that the cost per median month of survival for daratumumab was lower compared with 2 other novel treatments in multiple myeloma.

The Department of Justice has announced that Genentech and OSI Pharmaceuticals “will pay $67 million to resolve False Claim Act allegations that they made misleading statements about the effectiveness of the drug Tarceva to treat non-small cell lung cancer.”

Many patients 65 years or younger are still receiving aggressive cancer treatment in their final months of life despite Choosing Wisely recommendations encouraging symptom-directed palliative care.

Can the Oncotype DX Breast Cancer Assay impact recommendation and receipt of chemotherapy in early stage breast cancer? Does the test also improve patient experience? These were some of the questions asked by researchers at the University of Michigan, and the results presented during the annual meeting of the American Society of Clinical Oncology.

What we're reading, June 7, 2016: opioid restrictions disproportionately affect older patients with chronic pain; Genentech and OSI Pharmaceuticals settle Tarceva lawsuit; and trouble raising Zika virus funds.

The American Society of Clinical Oncology’s first-ever clinical trial is growing with the addition of its seventh and eighth pharmaceutical companies, Bayer and Merck, and 30 additional trial participants.

With value frameworks still in their infancy, Michael Kolodziej, MD, national medical director for oncology strategy at Aetna, doesn't see how his company can use them just yet. In fact, these frameworks may never be used by insurers, but only for shared decision making between the patient and provider.

A session at the ongoing annual meeting of the American Society of Clinical Oncology (ASCO) provided an overview of ASCO's recently updated value framework and their quality program, the Quality Oncology Practice Initiative.

The first study sheds light on the complex interaction between underlying metabolic risk and breast cancer.

What we're reading, June 6, 2016: Vice President Joe Biden will announce the launch of an open-access cancer research database, and a new bill in Congress would allow companies to repurpose existing drugs for rare diseases.